Riddhi Siddhi Gluco Biols Falls to 52-Week Low of Rs.451.6 Amidst Continued Downtrend

Intraday Price Movement and Volatility

On 2 December 2025, Riddhi Siddhi Gluco Biols recorded an intraday high of Rs.502, representing a 2.6% rise from the previous close. However, the stock also touched an intraday low of Rs.451.6, a 7.7% drop within the same trading session. This wide price range contributed to an intraday volatility of 5.29%, calculated from the weighted average price, indicating heightened trading activity and uncertainty among market participants.

The stock’s performance today showed a decline of 3.99%, underperforming its sector by 4.15%. This follows a two-day consecutive fall, during which the stock has returned -5.63%, reflecting sustained pressure on the share price.

Technical Indicators and Moving Averages

Riddhi Siddhi Gluco Biols is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning suggests a persistent bearish trend in the stock’s price action over both short and long-term horizons. The stock’s 52-week high stands at Rs.700, highlighting the extent of the decline from its peak.

Market Context and Comparative Performance

While Riddhi Siddhi Gluco Biols has faced a challenging period, the broader market has shown relative resilience. The Sensex opened 316.39 points lower and was trading at 85,311.48, down 0.39% on the day. Notably, the Sensex remains close to its 52-week high of 86,159.02, just 0.99% away, and is positioned above its 50-day moving average, which itself is above the 200-day moving average, signalling a generally bullish market trend.

In contrast, Riddhi Siddhi Gluco Biols has delivered a one-year return of -29.48%, significantly lagging behind the Sensex’s 6.30% gain over the same period. This divergence underscores the stock’s underperformance relative to the broader market.

Financial Performance and Growth Trends

The company’s financial metrics reveal a subdued growth trajectory. Over the past five years, net sales have shown a compound annual growth rate (CAGR) of -14.03%, indicating contraction rather than expansion. Earnings before interest and tax (EBIT) to interest ratio averages at -1.18, reflecting challenges in covering interest expenses from operating profits.

Riddhi Siddhi Gluco Biols has reported losses in recent quarters, with negative returns on capital employed (ROCE). The latest six-month profit after tax (PAT) stands at Rs.24.29 crores, showing a decline of 40.98%. Quarterly net sales have fallen by 34.36% to Rs.32.10 crores, while profit before tax excluding other income (PBT less OI) registered a loss of Rs.4.05 crores, a 225% decline.

Valuation and Risk Considerations

The stock’s earnings before interest, tax, depreciation and amortisation (EBITDA) remain negative, contributing to a riskier valuation profile compared to its historical averages. Over the past year, profits have declined by 18.7%, aligning with the stock’s negative return of 29.48%. Additionally, the stock has underperformed the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in both near and long-term performance.

Shareholding and Industry Position

Riddhi Siddhi Gluco Biols operates within the Trading & Distributors sector, with promoters holding the majority shareholding. The company’s market capitalisation grade is noted as 4, reflecting its size and market presence within the sector.

Summary of Recent Trends

The stock’s recent trajectory has been marked by a steady decline, with the 52-week low of Rs.451.6 representing a key technical milestone. The combination of subdued sales growth, negative profitability metrics, and trading below all major moving averages paints a picture of ongoing headwinds. Despite the broader market’s relative strength, Riddhi Siddhi Gluco Biols continues to face challenges in reversing its downward trend.

Investors and market watchers will note the stock’s high intraday volatility and underperformance relative to sector peers and the Sensex. The company’s financial results over the last three quarters have been negative, with key indicators such as PAT and net sales showing contraction. These factors contribute to the current market assessment and valuation environment surrounding the stock.

Conclusion

Riddhi Siddhi Gluco Biols’ fall to a 52-week low of Rs.451.6 highlights a period of sustained pressure on the stock price amid challenging financial and market conditions. The stock’s position below all major moving averages, coupled with negative earnings trends and subdued sales growth, reflects the difficulties faced by the company within the Trading & Distributors sector. While the broader market maintains a more positive stance, the stock’s performance remains subdued, underscoring the importance of closely monitoring its financial and market developments going forward.

Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →